SCHEMBL1968660

SCHEMBL1968660

CNC(C)(C(=O)O)c1ccc(OC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.51
ALOX15 P16050 2/20 0.50
PLK1 P53350 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
APEX1 P27695 1/20 0.50
MAPK1 P28482 1/20 0.50
RECQL P46063 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
MEN1 O00255 1/20 0.44
EPHX2 P34913 1/20 0.44
KMT2A Q03164 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968816 1.00 MAPT (0.51) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL1968288 0.86 MAPT (0.51) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL23797844 0.84 CA1 (0.51) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL1970964 0.83 MAPT (0.49) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL1969127 0.83 MAPT (0.49) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL1969125 0.83 MAPT (0.49) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL1972154 0.81 ALDH1A1 (0.50) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL7042241 0.81 NPSR1 (0.50) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL27432969 0.81 NPSR1 (0.50) MAPTALOX15PLK1ALDH1A1LMNA
SCHEMBL28746937 0.79 ESR1 (0.46) ALDH1A1LMNAHSD17B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 US disclosed
EP-2026799-B1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2011-06-22 EP disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 US disclosed
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such SASU, GALAPAGOS (FR) 2010-03-11 US disclosed
EP-2026799-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH Galapagos SAS (FR) 2009-02-25 EP disclosed
WO-2007137874-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH NR5A1, AR, HSD17B7 MAPT 4672/4885ALOX15 1084/4885PLK1 4858/4885
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such NR5A1, AR, HSD17B7 MAPT 4684/4885ALOX15 1040/4885PLK1 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.